Loading...
Loading...
JP Morgan maintained Cintas
CTAS with an Overweight rating and raised the price target from $47.00 to $50.00.
JP Morgan analyst Andrew C. Steinerman commented, "Thursday evening, Cintas reported 3QF13 (Feb) revenues of $1,076mln, ~2% above our estimate, as organic same-day basis (SDB) revenue growth rose to 6.9% y/y (from 3.4% y/y in 2QF13 (Nov)). 3QF13 EPS was $0.60, slightly below our estimate of $0.63. … The new healthcare regulations represent a prospective CY2014 margin headwind, but in a healthy economy CTAS should have high enough top-line growth and operating levers to overcome this headwind, in our view."
Cintas closed at $45.93 on Tuesday.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in